Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(6 sites)
United States
Florida Cancer Specialists, Sarasota, Florida Columbia University, New York, New York Brown University, Providence, Rhode Island France
Oncopole Claudius Regaud, Toulouse Centre Oscar Lambret, Villejuif